Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH
- PMID: 28861725
- PMCID: PMC5978896
- DOI: 10.1007/s12094-017-1740-0
Proposal for the creation of a national strategy for precision medicine in cancer: a position statement of SEOM, SEAP, and SEFH
Abstract
Precision medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person. Precision medicine is transforming clinical and biomedical research, as well as health care itself from a conceptual, as well as a methodological viewpoint, providing extraordinary opportunities to improve public health and lower the costs of the healthcare system. However, the implementation of precision medicine poses ethical-legal, regulatory, organizational, and knowledge-related challenges. Without a national strategy, precision medicine, which will be implemented one way or another, could take place without the appropriate planning that can guarantee technical quality, equal access of all citizens to the best practices, violating the rights of patients and professionals, and jeopardizing the solvency of the healthcare system. With this paper from the Spanish Societies of Medical Oncology, Pathology, and Hospital Pharmacy, we highlight the need to institute a consensual national strategy for the development of precision medicine in our country, review the national and international context, comment on the opportunities and challenges for implementing precision medicine, and outline the objectives of a national strategy on precision medicine in cancer.
Keywords: Consensus; Oncology; Precision medicine.
Conflict of interest statement
Conflict of interest
Dr. P. Garrido is advisory board member for Roche, Pfizer, Abbvie, AstraZeneca, Novartis, Guardant, BMS, Boehringher, and MSD and has received speaker honorarium from Roche, BMS, Boehringher, Pfizer. The remaining authors declare that they have no conflict of interest.
Ethical standards
The manuscript does not contain clinical studies or patient data.
References
- 
    - National Institute of Health. What is precision medicine? https://ghr.nlm.nih.gov/primer/precisionmedicine/definition. Accessed 5 Aug 2017.
 
- 
    - ICPerMed International Consortium. Action plan. Actionable research and support activities identified by the International Consortium for Personalised Medicine. 2017. http://www.icpermed.eu/media/content/ICPerMed_Actionplan_2017_web.pdf. Accessed 5 Aug 2017.
 
- 
    - Comisión Europea. Horizon 2020 en breve. El Programa Marco de Investigación e Innovación de la Unión Europea. Lux Oficina de Publicaciones de la Unión Europea, 2014. doi:10.2777/80075. http://ec.europa.eu/programmes/horizon2020/sites/horizon2020/files/H2020.... Accessed 5 Aug 2017.
 
- 
    - Aviesan, Alliance Nationale pour les Sciences de la Vie et de la Santé. France Médecine Génomique 2025. http://presse.inserm.fr/wp-content/uploads/2016/06/Plan-France-me%CC%81d.... Accessed 5 Aug 2017.
 
- 
    - The White House. Fact sheet: President Obama’s precision medicine initiative. Lister Hill National Centre for Biomedical Communications. U.S. National Library of Medicine. National Institutes of Health. Dept of Health & Human Services. 2017. https://obamawhitehouse.archives.gov/the-press-office/2015/01/30/fact-sh.... Accessed 5 Aug 2017.
 
MeSH terms
LinkOut - more resources
- Full Text Sources
- Other Literature Sources
 
        